Nasdaq ubx.

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...Find the latest Earnings Report Date for Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com.SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...

The latest price target for . Unity Biotechnology (NASDAQ: UBX) was reported by Wedbush on November 16, 2023.The analyst firm set a price target for $0.00 expecting UBX to fall to within 12 months ...

Find real-time UBX - UNITY Biotechnology Inc stock quotes, company profile, news and forecasts from CNN Business.Oct 5, 2022 · At $8, the average UBX price target implies upside potential of 1,829%. At writing, shares are trading at $0.41 for a market cap of approximately $56.8 million and has a 52-week range of $0.38 ...

Follow. SOUTH SAN FRANCISCO, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or ...SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...Find the latest news headlines from Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com. Feb 14, 2022 · SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ... About Unity Biotechnology (UBX) Earnings Date, Estimates & Call Transcripts $1.92 0.00 (0.00%) (As of 12/1/2023 ET) Compare Today's Range $1.86 $2.04 50-Day …

View the latest Unity Biotechnology Inc. (UBX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...Oct 17, 2023 · Unity Biotechnology (NASDAQ: UBX) primarily focuses on developing therapeutics targeting age-related ophthalmologic and neurologic diseases. Its main candidate, UBX1325, is being studied for ... Unity Biotechnology, Inc. (NASDAQ:UBX) shareholders should be happy to see the share price up 23% in the last month. But only the myopic could ignore the astounding decline over three years.Mar 15, 2023 · SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ... SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...SAN FRANCISCO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or ...

Last November, Wedbush analyst Andreas Argyrides raised his price target on Unity Biotechnology, Inc. (NASDAQ:UBX) to $36 from $4 and maintained an Outperform rating on the shares.Stable Share Price: UBX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. Volatility Over Time : UBX's weekly …Oliver Dolan MBA, CPA. Biotech/Healthcare Finance Executive. UNITY Biotechnology Inc. (Nasdaq : UBX) MIT Sloan School of Management ...SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...Discover historical prices for UBX stock on Yahoo Finance. View daily, weekly or monthly format back to when Unity Biotechnology, Inc. stock was issued.

Nov 24, 2023 · UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds. SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or rev... 15 days ago - GlobeNewsWire. SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging ...

SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today ...Unity Biotechnology, Inc. ( NASDAQ:UBX ) shareholders should be happy to see the share price up 23% in the last week...SOUTH SAN FRANCISCO, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases. UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz ...SAN FRANCISCO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or ...Third Quarter Financial Results. Cash, cash equivalents, and marketable securities totaled $88.5 million as of September 30, 2021 compared with $115.6 million as of December 31, 2020. UNITY ...Follow. SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or ...TARGETING A ROOT CAUSE. Age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burden for …

UNITY to host conference call on July 27, 2021, at 8:00 a.m. PT (11:00 a.m. ET) SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX ...

SOUTH SAN FRANCISCO, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...Dec 1, 2023 · Unity Biotechnology (UBX) Insider Trading Activity 2023. MarketBeat Week in Review – 11/27 - 12/1. Teen girls are being victimized by deepfake nudes. One family is pushing for more protections. S&P 500 4,594.63. DOW 36,245.50. The average one-year price target for Unity Biotechnology (NASDAQ:UBX) has been revised to 6.63 / share. This is an increase of 8.33% from the prior estimate of 6.12 dated …SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting ...The average one-year price target for Unity Biotechnology (NASDAQ:UBX) has been revised to 6.63 / share. This is an increase of 8.33% from the prior estimate of 6.12 dated October 31, 2023. SOUTH SAN FRANCISCO, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...August 16, 2022 16:01 ET | Source: Unity Biotechnology, Inc. SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology ...SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...

SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing ...Apr 28, 2021 · Follow. SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or ... The latest price target for . Unity Biotechnology (NASDAQ: UBX) was reported by Wedbush on November 16, 2023.The analyst firm set a price target for $0.00 expecting UBX to fall to within 12 months ... Unity Biotechnology (NASDAQ: UBX) primarily focuses on developing therapeutics targeting age-related ophthalmologic and neurologic diseases. Its main candidate, UBX1325, is being studied for ...Instagram:https://instagram. carlyle captrustwhat state quarters are worth moneybest preferred stock fundscable tv stocks Register for your free account today at data.nasdaq.com. About Pre-Market Quotes Nasdaq provides market information before market opens daily from 4:15 A.M. ET to …SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging ... demo trading forexnyse squarespace Mar 27, 2023 · This has heavy trading pulling shares of UBX stock lower today. Unity Biotechnology (NASDAQ: UBX) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of ... pb. SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing ...16th Annual Citi BioPharma Conference on September 8-10, 2021 Morgan Stanley 19th Annual Global Healthcare Conference on September 9-15, 2021 23rd...Last November, Wedbush analyst Andreas Argyrides raised his price target on Unity Biotechnology, Inc. (NASDAQ:UBX) to $36 from $4 and maintained an Outperform rating on the shares.